Trastuzumab: A Cardiologist’s Perspective
Author Information
Author(s): Côté Marc André MD FRCP(C)
Primary Institution: Laval University, Centre des maladies du sein Deschênes–Fabia, CHAUQ, Quebec City, Québec
Conclusion
Trastuzumab has significant benefits for HER2-positive breast cancer patients, but its potential cardiotoxicity requires careful monitoring.
Supporting Evidence
- About 80% of patients receiving trastuzumab maintain a normal left ventricular ejection fraction.
- The risk of severe cardiotoxicity from trastuzumab is rare, occurring in 0.6% to 4% of patients.
- An asymptomatic drop in left ventricular ejection fraction can lead to treatment stoppage in 14.2% of patients.
Takeaway
Trastuzumab helps many breast cancer patients, but it can sometimes hurt their hearts, so doctors need to watch them closely.
Methodology
Review of randomized clinical trials regarding trastuzumab and its cardiotoxic effects.
Potential Biases
The article may reflect the author's perspective as a cardiologist, which could introduce bias in interpreting the effects of trastuzumab.
Limitations
The long-term effects of trastuzumab on patients with prior cardiac issues are unclear, and many patients in clinical studies were excluded due to existing heart problems.
Want to read the original?
Access the complete publication on the publisher's website